Theranexus SA

ALTHX · PA · Healthcare / Biotechnology

3.32EUR-0.16 (-4.60%)

Price History

Full chart

Market Stats

Previous Close3.48

Open3.48

Day Range3.28 – 3.48

52-Week Range1.49 – 4.75

Volume50.13K

Market Cap45.78M

P/E (TTM)0.00

Forward P/E0.00

EPS-0.11

Dividend Yield0.00%

Beta1.51

50-Day Avg3.89

200-Day Avg3.31

About

THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for rare neurological disease, as well as TX01 for the treatment of Gaucher disease and Niemann-Pick type C diseases. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonyme in September 2025. The company was founded in 2013 and is headquartered in Lyon, France.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Mathieu Charvériat
Employees12
Headquarters60, Avenue Rockefeller, Lyon, France, 69008, France
Websitehttps://www.theranexus.com

Leadership

Mr. Mathieu CharvériatCo-Founder, CEO & Chairman
Mr. Franck MouthonCo-Founder & Director
Mr. Julien VeysDeputy CEO, COO & Director
Ms. Christine PlacetAdministrative & Financial Director · b. 1963
Ms. Francoise Vincent-LarrodeDirector of Human Resources
Ms. Marie SebilleChief Medical Officer

Financials

Income Statement

Currency: EUR	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	561.36K	90.56K	147.83K	110.93K	563.85K	294.61K	602	414.90K	296.33K	2.28M	0
Growth (%)	-	-83.87%	+63.23%	-24.96%	+408.30%	-47.75%	-99.80%	+68819.93%	-28.58%	+670.55%	-100.00%
Cost of Revenue	1.12M	1.44M	1.48M	6.68M	7.31M	5.61M	8.82M	332.00K	4.94M	2.62M	108.60K
Gross Profit	-558.09K	-1.35M	-1.33M	-6.57M	-6.74M	-5.31M	-8.82M	82.90K	-4.64M	-333.55K	-108.60K
Gross Margin	-99.42%	-1488.90%	-899.20%	-5921.14%	-1196.20%	-1803.56%	-1465443.52%	19.98%	-1565.37%	-14.61%	-
Operating Expense	558.26K	710.09K	1.39M	533.12K	1.20M	1.08M	690.84K	6.34M	3.00M	4.48M	10.12M
Operating Income	-1.12M	-2.06M	-2.72M	-7.10M	-7.94M	-6.39M	-9.51M	-6.26M	-7.64M	-4.81M	-10.23M
Operating Margin	-198.87%	-2272.96%	-1837.54%	-6401.73%	-1408.28%	-2170.21%	-1580201.00%	-1508.08%	-2579.44%	-210.66%	-
EBITDA	-1.10M	-2.04M	-2.69M	-6.94M	-7.36M	-5.33M	-8.67M	-5.93M	-7.39M	-2.53M	-10.12M
EBITDA Margin	-196.47%	-2248.25%	-1820.00%	-6251.97%	-1305.50%	-1809.34%	-1440519.10%	-1428.10%	-2492.90%	-110.81%	-
Net Income	-518.65K	-1.59M	-2.11M	-5.30M	-5.58M	-4.80M	-8.15M	-6.57M	-6.83M	-1.77M	-3.00M
Net Income Margin	-92.39%	-1752.11%	-1430.55%	-4778.40%	-989.58%	-1628.46%	-1353889.37%	-1582.80%	-2304.16%	-77.30%	-
R&D	1.53M	1.89M	1.89M	5.36M	5.64M	3.77M	5.55M	3.92M	7.54M	2.67M	861.00K
R&D as % of Total Revenue	272.73%	2085.79%	1277.80%	4831.92%	1000.97%	1280.34%	922591.36%	945.77%	2545.46%	117.07%	-
Interest Expense	16.75K	114.80K	128.66K	56.45K	102.93K	84.65K	33.20K	158.00K	83.97K	152.86K	99.42K
Interest Expense % of Total Revenue	2.98%	126.76%	87.03%	50.89%	18.25%	28.73%	5515.12%	38.08%	28.33%	6.69%	-

Balance Sheet

Currency: EUR	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	2.73M	2.88M	20.38M	18.85M	15.37M	17.47M	16.89M	12.05M	7.24M	3.74M	10.54M
Total Liabilities	1.05M	2.79M	1.66M	5.44M	5.39M	7.19M	6.71M	6.33M	5.02M	5.40M	7.64M
Total Equity	1.68M	89.85K	18.71M	12.87M	9.44M	8.72M	8.72M	5.73M	2.22M	-1.66M	1.99M
Cash	59.25K	1.15M	3.22M	7.15M	3.43M	8.71M	5.52M	2.10M	1.20M	714.31K	740.98K
Total Debt	500.46K	2.10M	533.21K	4.15M	3.47M	6.50M	6.46M	6.17M	3.64M	2.87M	2.88M
Net Debt	441.21K	603.73K	-2.76M	-3.69M	-648.13K	-3.01M	-192.75K	2.78M	2.44M	2.16M	2.14M

Cash Flow

Currency: EUR	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-867.96K	-1.47M	-1.89M	-5.60M	-5.07M	-5.68M	-6.25M	-5.37M	-6.36M	-3.37M	-883.76K
Investing Cash Flow	-62.18K	-165.62K	-350.38K	-461.13K	-2.11M	-252.05K	-150.62K	323.53K	-61.11K	77.04K	-168.23K
Financing Cash Flow	348.49K	1.68M	18.97M	3.00M	1.46M	7.69M	7.71M	1.63M	2.22M	-646.42K	7.85M
Capital Expenditure	49.18K	169.00K	149.27K	328.62K	2.11M	252.05K	150.62K	41.22K	43.61K	32.72K	56.05K
Free Cash Flow	-917.13K	-1.64M	-2.04M	-5.93M	-7.18M	-6.00M	-6.40M	-5.41M	-6.40M	-3.40M	-939.81K
FCF to OCF	105.67%	111.46%	107.89%	105.87%	141.58%	105.70%	102.41%	100.77%	100.69%	100.97%	106.34%

Earnings

Report Date	Oct 11, 2017	Apr 26, 2018	Oct 1, 2018	Apr 17, 2019	Nov 26, 2019	Apr 9, 2020	Dec 11, 2020	Apr 7, 2021	Sep 30, 2021	Apr 25, 2022	Jul 12, 2022	Apr 12, 2023	Sep 26, 2024	Apr 29, 2025	Sep 24, 2025
EPS Estimate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.94	0.00	0.00	-	0.00	0.00	0.00	0.00
EPS Actual	-0.42	-0.83	-1.22	-0.71	-0.89	-0.68	-0.79	-0.42	-0.82	-1.62	-0.65	-1.31	0.01	-0.20	-0.11
Surprise	-	-	-	-	-	-	-	55.32%	-	-	-	-	-	-	-
Timing	After-hours	After-hours	-	Pre-market	-	After-hours	-	After-hours	After-hours	Pre-market	After-hours	After-hours	-	-	-

Key Statistics & Ratios

Market Cap45.78M

Enterprise Value43.64M

Trailing P/E0.00

Forward P/E0.00

Price / Sales56.80

Price / Book16.72

EPS-0.11

Book Value0.21

Revenue (TTM)806.04K

Gross Profit (TTM)-1.43M

EBITDA-3.94M

Profit Margin0.00%

Operating Margin-99999999.99%

Return on Equity-482.39%

Return on Assets-35.43%

Shares Outstanding14.49M

Shares Float13.13M

Beta1.51

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Stock Splits

Oct 27, 2025779:749